Acetylcysteine
- Generic Name
- Acetylcysteine
- Brand Names
- Acetadote
- Drug Type
- Small Molecule
- Chemical Formula
- C5H9NO3S
- CAS Number
- 616-91-1
- Unique Ingredient Identifier
- WYQ7N0BPYC
- Background
Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.
Acetylcysteine was granted FDA approval on 14 September 1963.
- Indication
Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.
- Associated Conditions
- Acetaminophen Overdose, Chronic Rhinitis, Corneal Diseases, Corneal ulceration, Crusting Rhinitis, Keratopathy, Rhinitis, Sinusitis, Vasomotor Rhinitis, Acute Rhinitis, Subacute Rhinitis
- Associated Therapies
- Airway secretion clearance therapy
The Effects of N-acetylcysteine on Performance and Redox Homeostasis
- Conditions
- Interventions
- First Posted Date
- 2017-04-20
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Target Recruit Count
- 36
- Registration Number
- NCT03121222
- Locations
- 🇨🇾
European University Cyprus, Nicosia, Cyprus
🇬🇷National and Kapodistrian University of Athens, Athens, Greece
🇬🇷Aristotle University of Thessaloniki, Thessaloniki, Greece
Study to Evaluate the Feasibility of 13-C Pyruvate Imaging in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2017-04-20
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Registration Number
- NCT03121989
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?
- Conditions
- Interventions
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 6
- Registration Number
- NCT03104725
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Feasibility Study of N-acetylcysteine for Self-injurious Behavior in Children With Autism Spectrum Disorder
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Emory University
- Target Recruit Count
- 8
- Registration Number
- NCT03008889
- Locations
- 🇺🇸
Marcus Autism Center, Atlanta, Georgia, United States
N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders
- Conditions
- Interventions
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Tianjin Anding Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT02972398
- Locations
- 🇨🇳
Tianjin Anding Hospital, Tianjin, Tianjin, China
G-CSF Plus NAC In Severe Alcoholic Hepatitis
- Conditions
- Interventions
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2017-09-19
- Target Recruit Count
- 60
- Registration Number
- NCT02971306
- Locations
- 🇮🇳
Dept of Hepatology, PGIMER, Chandigarh, India
NAC for Treating Comorbid PTSD and SUD
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 90
- Registration Number
- NCT02911285
- Locations
- 🇺🇸
Ralph H Johnson VA Medical Center, Charleston, South Carolina, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy
- First Posted Date
- 2016-08-29
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 20
- Registration Number
- NCT02882477
- Locations
- 🇮🇱
Hadassah medical center, Jerusalem, Israel
Evaluation of Aerosolized Drugs Deposition During Mechanical Ventilation
- Conditions
- Interventions
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Chang Gung University
- Target Recruit Count
- 30
- Registration Number
- NCT02818270
- Locations
- 🇨🇳
Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI
- Conditions
- Interventions
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 30
- Registration Number
- NCT02791945
- Locations
- 🇺🇸
San Francisco VA Medical Center, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.